Relationship between 99Tcm-MDP uptake and bone mineral density in patients with prostatic carcinoma.
Seventeen men with prostatic carcinoma were investigated with quantitative bone scintigraphy and quantitative computed X-ray tomography before orchiectomy and up to 6 months after this operation. The uptake of 99Tcm-labelled methylene disphosphonate (99Tcm-MDP) and bone mineral density (BMD) were determined for each vertebra from Th10 to L4. Ten patients had normal scintigrams. No change in MDP uptake or BMD was seen after 6 months in these patients. Of the seven patients with abnormal scintigrams, one patient had a clinical sign of progression with an increase in both MDP uptake and BMD. The remaining six patients showed stable or improved clinical status. For their abnormal vertebrae a decrease in MDP uptake was seen, while BMD varied in different ways after 6 months. For the normal vertebrae in these patients with metastatic involvement, no change in MDP uptake was seen. However, the BMD values showed a decrease, indicating a generalized increase in bone resorption at sites distant from the metastases.
Department of Clinical Physiology, Lund University, Malmö General Hospital, Sweden.
G M
GM
Sundkvist
M
M
Nilsson
L
L
Ahlgren
B
B
Lilja
S
S
Mattsson
M
M
Birch-Iensen
P A
PA
Abrahamsson
D000368:Aged; D000369:Aged, 80 and over; D015519:Bone Density / Q000502:physiology*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000453:epidemiology / Q000601:surgery; D011877:Radionuclide Imaging; D013125:Spinal Neoplasms / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000556:secondary; D013669:Technetium Tc 99m Medronate / Q000493:pharmacokinetics*
D013669:Technetium Tc 99m Medronate